There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BridgeBio Pharma (BBIO – Research Report), Aurinia Pharmaceuticals (AUPH – Research Report) and 908 Devices (MASS – Research Report) with bullish sentiments.
Aurinia Pharmaceuticals (AUPH)
In a report issued on April 30, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Aurinia Pharmaceuticals. The company’s shares closed last Wednesday at $5.20, close to its 52-week low of $4.71.
According to TipRanks.com, Schwartz is a 1-star analyst with an average return of
Aurinia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $10.00.
908 Devices (MASS)
Leerink Partners analyst Puneet Souda reiterated a Buy rating on 908 Devices on April 30 and set a price target of $15.00. The company’s shares closed last Wednesday at $5.68, close to its 52-week low of $4.85.
According to TipRanks.com, Souda is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on 908 Devices is a Strong Buy with an average price target of $16.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BBIO:
- 3 Best Stocks to Buy Now, 5/1/2024, According to Top Analysts
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio reports inducement grants under Nasdaq listing rule
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
